Literature DB >> 18793660

Withdrawal effects from progesterone and estradiol relate to individual risk-taking and explorative behavior in female rats.

Magnus Löfgren1, Inga-Maj Johansson, Bengt Meyerson, Sahruh Turkmen, Torbjörn Bäckström.   

Abstract

Withdrawal from progesterone and estradiol has been used as an animal model of premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD). In the clinical population individual sensitivity to sex steroid hormones, personality and heredity influence PMS/PMDD. Understanding the phenotypic risk factors of PMS/PMDD and drug development requires an animal model which incorporates individual steroid sensitivity. The main objective of this study was to investigate whether the individual trait of risk-taking and exploration influence the severity of PEWD in female rats. Thirty-two female Wistar rats in their diestrus phase were tested in the open field (OF) and divided into high responders (HR) and low responders (LR). Injections were given i.p. twice daily for 6 days, either 5 mg/kg progesterone combined with 10 microg/kg 17beta-estradiol, or vehicle (sesame oil). After a 24-hour withdrawal the animals were tested in the elevated plus maze (EPM). Blood samples for CORT analysis were collected after both behavioral tests. The HR rats withdrawn from progesterone and estradiol, spent less time on the EPM open arms and had lower CORT levels than the HR controls. The LR group showed no differences in EPM behavior and CORT levels during PEWD. The controls showed a stable trait of risk-taking and exploration, indicated by behavioral and CORT level correlations between the OF and EPM tests. These findings show that female rats with the trait of risk-taking and explorative behavior (HR) are more affected by PEWD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18793660     DOI: 10.1016/j.physbeh.2008.08.015

Source DB:  PubMed          Journal:  Physiol Behav        ISSN: 0031-9384


  8 in total

1.  Progesterone receptor antagonist CDB-4124 increases depression-like behavior in mice without affecting locomotor ability.

Authors:  Ethan H Beckley; Angela C Scibelli; Deborah A Finn
Journal:  Psychoneuroendocrinology       Date:  2010-12-15       Impact factor: 4.905

2.  Effect of diet on brain metabolites and behavior in spontaneously hypertensive rats.

Authors:  Ana A Liso Navarro; Elif M Sikoglu; Cailin R Heinze; Ryan C Rogan; Vivienne A Russell; Jean A King; Constance M Moore
Journal:  Behav Brain Res       Date:  2014-05-19       Impact factor: 3.332

3.  Agonistic behavior in males and females: effects of an estrogen receptor beta agonist in gonadectomized and gonadally intact mice.

Authors:  Amy E Clipperton Allen; Cheryl L Cragg; Alexis J Wood; Donald W Pfaff; Elena Choleris
Journal:  Psychoneuroendocrinology       Date:  2010-02-02       Impact factor: 4.905

4.  Region-specific alteration in brain glutamate: possible relationship to risk-taking behavior.

Authors:  Bernadette M Cortese; Todd R Mitchell; Matthew P Galloway; Kristen E Prevost; Jidong Fang; Gregory J Moore; Thomas W Uhde
Journal:  Physiol Behav       Date:  2009-12-13

5.  Interactive effects of ovarian steroid hormones on alcohol use and binge drinking across the menstrual cycle.

Authors:  Michelle M Martel; Tory Eisenlohr-Moul; Bethan Roberts
Journal:  J Abnorm Psychol       Date:  2017-11

6.  Reproductive steroids and ADHD symptoms across the menstrual cycle.

Authors:  Bethan Roberts; Tory Eisenlohr-Moul; Michelle M Martel
Journal:  Psychoneuroendocrinology       Date:  2017-11-28       Impact factor: 4.905

7.  Risk-assessment and risk-taking behavior predict potassium- and amphetamine-induced dopamine response in the dorsal striatum of rats.

Authors:  Sara Palm; Shima Momeni; Stina Lundberg; Ingrid Nylander; Erika Roman
Journal:  Front Behav Neurosci       Date:  2014-07-15       Impact factor: 3.558

8.  Progesterone After Estradiol Modulates Shuttle-Cage Escape by Facilitating Volition.

Authors:  Darryl J Mayeaux; Sarah M Tandle; Sean M Cilano; Matthew J Fitzharris
Journal:  J Exp Neurosci       Date:  2016-01-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.